David R. Gandara, MD, discusses why PD-L1 scoring in NSCLC undercounts immunotherapy benefit and where TMB and plasma proteomics fit alongside it.
|Videos|May 18, 2011
Dr. Markman on Potential Neuropathy Biomarkers
Author(s)Maurie Markman, MD
Dr. Markman on Taxane-Induced Neuropathy Biomarkers
Advertisement
Maurie Markman, MD the National Director for Medical Oncology for the Cancer Treatment Centers of America on Taxane-Induced Neuropathy Biomarkers
Advertisement
Related to this article
Edgardo S. Santos Castillero, MD, discusses MAVERICK, B7-H3 ADC data, and tarlatamab sequencing in SCLC, plus molecular testing in a value-based practice.
Advertisement
Advertisement
Trending on OncLive
1
NAPISTAR-1-01 Data Support Rapid TUB-040 Development in Biomarker-Unrestricted Ovarian Cancer
2
FDA Grants Fast Track Designation to LYT-200 in R/R High-Risk MDS
3
Japan Approves Subcutaneous Pembrolizumab for All Approved Pembrolizumab Indications
4
Making Invisible Cancers Visible: Study Suggests a New Route to Turn ‘Cold’ Tumors ‘Hot’
5